产品名称
抗-表皮生长因子受体单克隆抗体 小鼠抗, clone F4, ascites fluid
biological source
mouse
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
primary antibodies
clone
F4, monoclonal
contains
15 mM sodium azide
species reactivity
human
packaging
antibody small pack of 25 μL
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
immunohistochemistry (frozen sections): suitable
immunoprecipitation (IP): suitable
indirect ELISA: suitable
microarray: suitable
western blot: 1:2,000
isotype
IgG1
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... EGFR(1956)
正在寻找类似产品? 访问 产品对比指南
Application
Monoclonal Anti-Epidermal Growth Factor Receptor antibody produced in mouse has been used in:
- western blotting
- immunoprecipitation
- immunocytochemistry
- immunohistochemical staining
Biochem/physiol Actions
EGFR is a transmembrane glycoprotein that binds to the EGF family. It is a pivotal regulator of cell proliferation, growth, differentiation and DNA repair after radiation-induced damage. Mutations in the gene encoding EGFR are associated with a number of malignancies including lung cancer and colorectal cancer.
Epidermal growth factor receptor (EGF-R) is a tyrosine-specific protein kinase with the capacity to phosphorylate tyrosine residues located near its carboxy-terminus.
This antibody recognizes specifically an intracellular domain of the EGF receptor.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
Monoclonal Anti-Epidermal Growth Factor (EGF) Receptor (mouse IgG1 isotype) is derived from the hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse. The receptor for epidermal growth factor is an integral cell membrane protein of 170 kD, which spans the membranes of a wide range of normal and malignant epithelial cells. EGF-R have been identified in sarcomas, gliomas, breast, bladder, lung and gynecological tumors. The EGF-R has a half-life of approximately 10 hours in human fibroblasts, but in the presence of EGF this value is reduced to about 1 hour.
Immunogen
synthetically produced residues 985-996 of the human EGF receptor.
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
此项目有
Mechanisms of receptor tyrosine kinase activation in cancer
Du Z and Lovly CM
Molecular Cancer, 17(1), 58-58 (2018)
Netanya I Pollock et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 21(20), 4597-4606 (2015-07-04)
In other cancer types, HPV infection has been reported to coincide with overexpression of HER2 (ERBB2) and HER3 (ERBB3); however, the association between HER2 or HER3 expression and dimer formation in HNSCC has not been reported. Overexpression of HER2 and
M S Berger et al.
The Journal of pathology, 152(4), 297-307 (1987-08-01)
Immunocytochemical analysis of epidermal growth factor (EGF) receptor expression was carried out on frozen sections of 109 primary lung tumours resected at the Brompton Hospital from February 1984 to May 1985. Tumours with detectable levels of this proto-oncogene protein were
Qing Cheng et al.
EJNMMI research, 6(1), 58-58 (2016-07-09)
Though overexpression of epidermal growth factor receptor (EGFR) in several forms of cancer is considered to be an important prognostic biomarker related to poor prognosis, clear correlations between biomarker assays and patient management have been difficult to establish. Here, we
A Argiris et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 24(1), 220-225 (2012-08-18)
We evaluated combined targeting with cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, and bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, in squamous cell carcinoma of the head and neck (SCCHN). The combination was studied in human
相关内容
View an automated protocol for Duolink® assays on the AAW™ automated assay workstation and see results comparing manual vs automated runs.
在 AAW™ 自动测试工作站上查看 Duolink® 检测的自动协议，并查看手动与自动运行的结果比较。
Datasheet
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持